Results 161 to 170 of about 926 (182)
Some of the next articles are maybe not open access.

Saroglitazar, a dual PPAR-α/γ agonist, alleviates LPS-induced hepatic and renal injury in rats

International Immunopharmacology, 2023
Ahmed R El-Sheakh   +2 more
exaly  

Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients

Journal of Clinical and Experimental Hepatology, 2022
Prateek Padole, Praveen Sharma
exaly  

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Clinical Gastroenterology and Hepatology, 2023
Mohammad Shadab Siddiqui   +2 more
exaly  

Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases

Atherosclerosis, 2019
M. Krishnappa   +5 more
openaire   +1 more source

Saroglitazar - A novel treatment for non-alcoholic steatohepatitis

AIP Conference Proceedings
Shifa Noorani   +8 more
openaire   +1 more source

Abstract #1311: Saroglitazar in Non-Alcoholic Fatty Liver Disease

Endocrine Practice, 2016
Shashank Joshi   +4 more
openaire   +1 more source

Home - About - Disclaimer - Privacy